Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective

被引：0
|
作者：
Malik, Shakun [1 ]
Justice, Robert [1 ]
Sridhara, Rajeshwari [1 ]
Waxman, Ian [1 ]
Pazdur, Richard [1 ]
机构：
[1] US FDA, CDER, Silver Spring, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S235 / S236
页数：2
相关论文
共 50 条
  • [1] Molecular targeted therapies: Ready for "prime time" in biliary tract cancer
    Lamarca, Angela
    Barriuso, Jorge
    McNamara, Mairead G.
    Valle, Juan W.
    JOURNAL OF HEPATOLOGY, 2020, 73 (01) : 170 - 185
  • [2] Targeted therapies prime lung cancer cells for macrophage-mediated destruction
    Vacarro, Kyle
    Allen, Juliet
    Maoz, Asaf
    Reeves, Sarah
    Hata, Aaron
    Weiskopf, Kipp
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies
    Tibau, Ariadna
    Hwang, Thomas J.
    Molto, Consolacion
    Avorn, Jerry
    Kesselheim, Aaron S.
    JAMA ONCOLOGY, 2024, 10 (05) : 634 - 641
  • [4] ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time
    Husain, Hatim
    Rudin, Charles M.
    ONCOLOGY-NEW YORK, 2011, 25 (07): : 597 - 601
  • [5] Imaging as a tumor biomarker in oncology drug trials for lung cancer: The FDA perspective
    Petrick, N.
    Brown, D. G.
    Suleiman, O.
    Myers, K. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (04) : 523 - 525
  • [6] Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
    Tibau, A.
    Hwang, T. J.
    Consolacion, M.
    Avorn, J.
    Kesselheim, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S930 - S930
  • [7] Cytoreductive nephrectomy and targeted therapies in metastatic renal cancer : new data pending for randomized trials
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2015, 25 (01): : F14 - F15
  • [8] Adverse kidney related events following targeted therapies in lung cancer: a systematic review and network meta-analysis of randomized controlled trials
    Ren, Song
    Wang, Wei
    Yao, Xiaoxiu
    Fang, Wenyan
    Li, Guisen
    Feng, Yunlin
    Xia, Min
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [9] Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer
    Eltawil, Karim M.
    Renfrew, Paul D.
    Molinari, Michele
    HPB, 2012, 14 (04) : 260 - 268
  • [10] Value of Molecular Targets and Genome-Targeted Therapies FDA-Approved for Metastatic Breast Cancer, 2006-2023
    Tibau, Ariadna
    Hwang, Thomas J.
    Valiente, Consolacion Molto
    Avorn, Jerry
    Kesselheim, Aaron
    CANCER RESEARCH, 2024, 84 (09)
12345